Hemostemix Inc. (HMTXF)
Hemostemix, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases. The firm's, ACP-01, lead clinical stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. The company was founded by Roger Bergersen and Thomas A. Smeenk in 2006 and is headquartered in Calgary, Canada.
Sector: Biotechnology
Industry: Biotechnology
Hemostemix Inc.
OTC:HMTXFHealthcare · Biotechnology
-31.71%$0.0239
CLOSED · Nov 16Prev close$0.0350-31.71%Close$0.0239
Mkt Cap$5.05M
EV-
Float168.41M
O/S211.44M
VOL79K sh
$ Vol$2K
RVOL1.85×
Inst Own-
SI<0.1%
Net Cash/Sh-
Dilution
MCap$5.05MFloat168.41MO/S211.44M
Dilution